Evidence map›Paper›PMID 42380594›Full record

Articlenpj drug discovery2026

MAMMAL - Molecular Aligned Multi-Modal Architecture and Language for biomedical discovery.

Yoel Shoshan, Moshiko Raboh, Michal Ozery-Flato, Vadim Ratner, Alex Golts, Jeffrey K Weber, Ella Barkan, Simona Rabinovici-Cohen, Sagi Polaczek, Ido Amos and 11 more

Abstract read
In one paragraph

Article in npj drug discovery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Yoel Shoshan *IBM Research-Israel, IBM Research, Haifa, Israel. yoels@il.ibm.com.
Moshiko Raboh *IBM Research-Israel, IBM Research, Haifa, Israel.
Michal Ozery-Flato *IBM Research-Israel, IBM Research, Haifa, Israel.
Vadim RatnerIBM Research-Israel, IBM Research, Haifa, Israel.
Alex GoltsIBM Research-Israel, IBM Research, Haifa, Israel.
Jeffrey K WeberIBM TJ Watson Research Center, IBM Research, New York, NY, USA.
Ella BarkanIBM Research-Israel, IBM Research, Haifa, Israel.
Simona Rabinovici-CohenIBM Research-Israel, IBM Research, Haifa, Israel.
Sagi PolaczekIBM Research-Israel, IBM Research, Haifa, Israel.
Ido AmosIBM Research-Israel, IBM Research, Haifa, Israel.
Ben ShapiraIBM Research-Israel, IBM Research, Haifa, Israel.
Liam HazanIBM Research-Israel, IBM Research, Haifa, Israel.
Matan NinioIBM Research-Israel, IBM Research, Haifa, Israel.
Sivan RavidIBM Research-Israel, IBM Research, Haifa, Israel.
Michael M DanzigerIBM Research-Israel, IBM Research, Haifa, Israel.
Yosi ShamayFaculty of Biomedical Engineering, Technion - IIT, Haifa, Israel.
Sharon KurantFaculty of Biomedical Engineering, Technion - IIT, Haifa, Israel.
Joseph A MorroneIBM TJ Watson Research Center, IBM Research, New York, NY, USA.
Parthasarathy SuryanarayananIBM TJ Watson Research Center, IBM Research, New York, NY, USA.
Michal Rosen-Zvi *IBM Research-Israel, IBM Research, Haifa, Israel.
Efrat Hexter *IBM Research-Israel, IBM Research, Haifa, Israel.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Modern AI (Artificial Intelligence) methods offer new opportunities in pharmacology by enabling improved modeling of disease mechanisms and drug action learned from large and heterogeneous biological datasets. A central challenge is developing models that can jointly integrate disparate biomedical modalities. We introduce MAMMAL (Molecular Aligned Multi Modal Architecture and Language), a foundation model for cross-modal learning, designed to address the challenges associated with drug discovery tasks. MAMMAL was pre-trained on 2 billion samples across protein and antibody sequences, small molecules, and gene expression profiles, and supports classification, regression, and generative tasks on cross-modal inputs. Across eleven benchmarks covering multiple stages of the drug discovery pipeline, MAMMAL achieves state-of-the-art performance on nine tasks and competitive results on two. In an antibody-antigen binding benchmark, fine-tuned MAMMAL prediction scores significantly outperform AlphaFold3 confidence scores, used here as a reference proxy for binding likelihood, in five of seven antigen targets. The MAMMAL framework and pretrained models are publicly available to support open and collaborative research.

Identifiers

PMID42380594
PMCPMC13267068

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.